11 results about "Esterified fatty acid" patented technology

A formulation comprising: at least one isocyanate compound; at least one bio-oil-based compound selected from the group consisting of triglyceride (TG)-based bio-oil compounds and esterified bio-based fatty acid compounds; optionally, a catalyst compound for promoting urea / polyurethane formation; the ratio of the TG-based bio-oil compound to the esterified fatty acid compound is from 60 / 40 to 0 / 100, preferably from 55 / 45 to 0 / 100, more preferably from 50 / 50 to 40 / 60, most preferably from 45 / 55 to 50 / 50, and the at least one isocyanate compound (a) is present in an amount of at least 90 wt%, based on 100 wt% of the total formulation.

A process including either transesterifying seed oils or animal fats with an octanol selected from the group consisting of n-octanol, iso-octanol, 2-ethylhexanol or mixtures thereof in the presence of a catalyst selected from alkali metal n-octoxide, alkali metal iso-octoxide or alkali metal 2-ethylhexoxide, or esterifying fatty acids with an octanol in the presence of a sulfonic acid, thereby forming methanol-free and ethanol-free octyl esters of fatty acids.

A method includes incubating a biological sample including a quantity of non-esterified fatty acids ("NEFA") with a reagent that includes a first component, a second component, and a third component. The first component is allowed to interact with the quantity of NEFA to generate a first reaction product. The first reaction product is allowed to interact with the second component to generate a second reaction product, and the second reaction product is allowed to interact with the third component to generate an indicator signal indicative of the quantity of NEFA. The indicator signal is interpreted as a determination of a quantity of the NEFA. The first reaction product, the second reaction product, and the indicator signal are generated in a single incubation operation. The reagent can include a first and a second reagent bead. The single incubation step can be performed in a rotor system.

The application discloses a system for predicting the occurrence time of the peak value of the non-esterified fatty acid concentration in the blood of a dairy cow after delivery, and belongs to the technical field of healthy breeding of dairy cows. The system takes the genus level relative abundance of five marker microorganisms in the intestinal contents of a dairy cow one week before delivery as input data, calculates a score through a preset discriminant model, and judges whether the peak value of the blood free fatty acid concentration after delivery occurs on the day of calving according to a set threshold. The overall prediction accuracy of the discriminant model reaches 90%, the prediction accuracy for dairy cows with a peak on the day of calving reaches 75%, the system is simple to operate and stable in performance, can realize pre-delivery early warning of high health risks of peripartum dairy cows, provides technical support for taking preventive measures in advance, improving the postpartum health status and lactation level of dairy cows, and has important practical application value and economic significance.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

The invention refers to a composition for the oxidative dyeing of keratinous fibers, particularly human hair, which comprises 2-methoxymethyl-p-phenylenediamine, one of its addition salts, its solvates and / or the solvates of its salts as well as at least one coupling agent chosen from 2-(1,3-benzodioxol-5-ylamino)ethanol, one of its addition salts, its solvates and / or the solvates of its salts. Moreover, it contains at least one fatty substance comprising at least one triglyceride. The amount of triglyceride constitutes at least 50 wt. % of the total fatty substance content, whereby the at least one triglyceride has at least one unsaturated double bond in at least one of the esterified fatty acid residues.

A method of forming a DHEA derivative supplement including adaptogens, modified stilbenoids complex, non-esterified omega-3 fatty acids, essential amino acids, HMB free acid, vitamins, L-arginine, creatine, green tea extracts, and chelated minerals, in a multi-bioavailability delivery system, based on the nature of the constituents, formed as an encapsulated micronized material having a phytosomal delivery system which reduces supplements dosage while increasing active nutrients efficacy and bioavailability by providing a targeted delivery system for nutritional effects.

A method includes incubating a biological sample including a quantity of non-esterified fatty acids ("NEFA") with a reagent that includes a first component, a second component, and a third component. The first component is allowed to interact with the quantity of NEFA to generate a first reaction product. The first reaction product is allowed to interact with the second component to generate a second reaction product, and the second reaction product is allowed to interact with the third component to generate an indicator signal indicative of the quantity of NEFA. The indicator signal is interpreted as a determination of a quantity of the NEFA. The first reaction product, the second reaction product, and the indicator signal are generated in a single incubation operation. The reagent can include a first and a second reagent bead. The single incubation step can be performed in a rotor system.

The invention discloses a system for predicting occurrence time of a concentration peak value of non-esterified fatty acid in postpartum blood of dairy cows, and belongs to the technical field of healthy breeding of dairy cows. According to the system, genus level relative abundance of five marker microorganisms in intestinal contents of dairy cows in a week before parturition is used as input data, a score is calculated through a preset judgment model, and whether a concentration peak value of free fatty acid in postpartum blood appears on the calving day or not is judged according to a set threshold value. The total prediction accuracy of the discrimination model reaches 90%, the prediction accuracy of the dairy cow reaching the peak on the day of calving is 75%, the operation is simple, the efficiency is stable, prenatal early warning of the high health risk of the dairy cow in the perinatal period can be realized, technical support is provided for taking prevention and control measures in advance and improving the postpartum health condition and lactation level of the dairy cow, and the method is suitable for popularization and application. The method has important practical application value and economic significance.

A process including either transesterifying seed oils or animal fats with an octanol selected from the group consisting of n-octanol, iso-octanol, 2-ethylhexanol or mixtures thereof in the presence of a catalyst selected from alkali metal n-octoxide, alkali metal iso-octoxide or alkali metal 2-ethylhexoxide, or esterifying fatty acids with an octanol in the presence of a sulfonic acid, thereby forming methanol-free and ethanol-free octyl esters of fatty acids.

The present application, provides, inter alia, a composition including an esterified fatty acid, including a fatty acid comprising 4 to 24 carbon atoms, for use in a method for prevention or treatment of a monogenean infection in an aquatic organism in need thereof.